Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico

• Francisca Sabugo S ^[1] ; Carolina Llanos M ^[1] ; Lilian Soto S ^[1] ; Jorge Gutiérrez ^[2] ; Miguel Cuchacovich T ^[1]
  1. [1] Universidad de Chile

     Universidad de Chile

     Santiago, Chile

     
  2. [2] Clínica Las Condes

     Clínica Las Condes

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 133, Nº. 6, 2005, págs. 681-684
• Idioma: español
• Títulos paralelos:
  • Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: Report of one case
• Enlaces
  • Texto completo
• Resumen

  • New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m² for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later